PDD Holdings to Report Q1 2026 Financial Results on May 27
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Earnings Report Schedule: PDD Holdings will announce its unaudited financial results for the first quarter ended March 31, 2026, before U.S. markets open on May 27, 2026, reflecting the company's commitment to transparency and information disclosure.
- Conference Call Timing: The company's management will hold an earnings conference call at 7:30 AM ET on May 27, 2026, aimed at sharing financial performance and future outlook with investors and analysts, thereby enhancing market confidence.
- Webcast Availability: The conference call will be webcast live on the company's investor website, with a replay available post-call, ensuring that investors unable to attend in real-time can access key information, thus improving information accessibility.
- Company Background: PDD Holdings is a multinational commerce group focused on bringing more businesses and individuals into the digital economy, enhancing productivity and new opportunities for local communities and small businesses, reflecting its strategic positioning in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PDD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PDD
Wall Street analysts forecast PDD stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 97.790
Low
118.00
Averages
146.39
High
167.00
Current: 97.790
Low
118.00
Averages
146.39
High
167.00
About PDD
PDD Holdings Inc. is a multinational commerce company that owns and operates a portfolio of businesses. The Company is focused on bringing businesses and people into the digital economy, which benefits local communities and small businesses from improved productivity and new opportunities. The Company has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses. Its Pinduoduo platform provides buyers with a comprehensive selection of value-for-money merchandise and fun and interactive shopping experiences. The Temu, a global e-commerce platform which brings together buyers, merchants, manufacturers, and brands from around the world, offers a selection of merchandise in product categories such as apparel, electronic appliances, household goods, sports and fitness, tools and home improvement, and pet supplies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lenovo's Performance Boost: Lenovo reported an 84% increase in AI-related revenue for Q4, leading to a nearly 20% surge in its stock price, which also propelled Dell and HP shares up over 15%, reflecting strong market demand and competitive positioning in AI technology.
- Estee Lauder's Stock Recovery: Estee Lauder's shares rose 10% despite ending merger talks with Puig, indicating robust market performance and a solid position in the cosmetics industry.
- Workday's Strong Results: Workday's stock jumped nearly 4% after posting better-than-expected earnings and raising its full-year margin outlook, showcasing its growth potential in finance and HR software.
- Merck's Drug Breakthrough: Merck's lung cancer treatment, developed in partnership with Kelun-Biotech, demonstrated a 65% reduction in tumor progression risk in a phase 3 study, resulting in a nearly 5% increase in stock price, reinforcing its competitive edge in oncology.
See More
- Estee Lauder Stock Surge: Estee Lauder's shares jumped nearly 10% despite ending merger talks with Puig, indicating increased market confidence in its independent operations, which may aid future strategic developments.
- Workday's Strong Performance: Workday's stock rose over 8% after reporting better-than-expected earnings and raising its full-year margin outlook, with co-founder Aneel Bhusri returning as CEO, potentially bringing new growth momentum to the company.
- Merck's Lung Cancer Treatment Progress: Merck's shares increased by almost 3.5% following a phase 3 study showing a 65% reduction in tumor progression risk for its lung cancer treatment in partnership with Kelun-Biotech, enhancing its competitive position in the oncology market.
- IMAX Exploring Sale: IMAX's stock surged 14% after reports emerged that the company is exploring a sale and had preliminary talks with potential buyers, which could provide new opportunities for strategic restructuring in the future.
See More
- Earnings Report Schedule: PDD Holdings will announce its unaudited financial results for the first quarter ended March 31, 2026, before U.S. markets open on May 27, 2026, reflecting the company's commitment to transparency and information disclosure.
- Conference Call Timing: The company's management will hold an earnings conference call at 7:30 AM ET on May 27, 2026, aimed at sharing financial performance and future outlook with investors and analysts, thereby enhancing market confidence.
- Webcast Availability: The conference call will be webcast live on the company's investor website, with a replay available post-call, ensuring that investors unable to attend in real-time can access key information, thus improving information accessibility.
- Company Background: PDD Holdings is a multinational commerce group focused on bringing more businesses and individuals into the digital economy, enhancing productivity and new opportunities for local communities and small businesses, reflecting its strategic positioning in the global market.
See More
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
- Market Recovery: Major Chinese companies including Alibaba, PDD, NetEase, and JD.com saw stock gains between 3% and 7% on Wednesday, reflecting market optimism ahead of the upcoming Trump-Xi summit.
- Small Caps Surge: Smaller Chinese firms like Dreamland Limited, Oriental Culture, and Antelope Enterprise experienced significant stock increases ranging from 25% to 67%, indicating strong investor interest and confidence in these companies.
- Summit Significance: The meeting between Trump and Xi marks their first encounter since 2017, with discussions expected to cover critical topics such as trade, policies, and national security, potentially providing clarity for global markets on future business conditions.
- Market Expectations: Investors on social media express optimism about the summit's outcomes, anticipating potential new tech deals between the U.S. and China, particularly involving Alibaba and Nvidia, which could attract significant market attention.
See More
- Copyright Infringement Allegations: Shein accuses Temu of using thousands of its photos to promote copies of its clothing, attempting to gain an unfair competitive advantage, highlighting the fierce rivalry in the global e-commerce market.
- Legal Counterclaims: Temu has dropped its defense against Shein's copyright claims over nearly 2,300 photos and has counterclaimed for damages after being forced to remove numerous product listings, illustrating the complexity of the legal battle.
- Competition Law Dispute: Temu alleges that Shein violated competition law by tying fast-fashion suppliers to exclusive agreements, with a trial on this matter scheduled for next year, which could impact industry supply chain dynamics.
- Changing Market Conditions: The removal of U.S. customs exemptions on low-value e-commerce parcels poses challenges for Shein and Temu's rapid expansion in international markets, potentially negatively affecting future growth.
See More










